|BioSante Pharmaceuticals, Inc.|
111 Barclay Boulevard
United States - Map
BioSante Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development of products for female sexual health, menopause, contraception, and male hypogonadism. It provides LibiGel, a daily transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Male testosterone gel, a daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypogonadism or testosterone deficiency in men; The Pill-Plus, a triple component contraceptive in Phase II development; and Elestrin, a daily transdermal estradiol gel approved by the FDA for the treatment of hot flashes associated with menopause and marketed in the United States by Meda Pharmaceuticals, Inc. The company licensed the technology underlying LibiGel and Elestrin from Antares Pharma, Inc. BioSante Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Lincolnshire, Illinois.
|Mr. Stephen M. Simes ,
Vice Chairman, Chief Exec. Officer and Pres
|Mr. Phillip B. Donenberg CPA,
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec.
|Ms. Joanne Zborowski ,
VP of Clinical Devel.
|Ms. Patricia M. Adams MSHR SPHR,
VP of Information Technology
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|